Cannell & Spears LLC Grows Stake in Abbott Laboratories $ABT

Cannell & Spears LLC increased its position in shares of Abbott Laboratories (NYSE:ABT) by 7.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 561,928 shares of the healthcare product maker’s stock after purchasing an additional 41,362 shares during the quarter. Abbott Laboratories accounts for 1.4% of Cannell & Spears LLC’s investment portfolio, making the stock its 17th biggest holding. Cannell & Spears LLC’s holdings in Abbott Laboratories were worth $75,265,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Cinctive Capital Management LP increased its position in shares of Abbott Laboratories by 87.3% in the third quarter. Cinctive Capital Management LP now owns 40,254 shares of the healthcare product maker’s stock valued at $5,392,000 after buying an additional 18,763 shares in the last quarter. Ausdal Financial Partners Inc. boosted its position in shares of Abbott Laboratories by 19.6% in the 3rd quarter. Ausdal Financial Partners Inc. now owns 6,958 shares of the healthcare product maker’s stock worth $932,000 after buying an additional 1,142 shares in the last quarter. Banco Bilbao Vizcaya Argentaria S.A. grew its stake in Abbott Laboratories by 9.9% in the 3rd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 157,256 shares of the healthcare product maker’s stock valued at $21,057,000 after acquiring an additional 14,112 shares during the last quarter. Chilton Investment Co. Inc. grew its stake in Abbott Laboratories by 19.5% in the 3rd quarter. Chilton Investment Co. Inc. now owns 25,916 shares of the healthcare product maker’s stock valued at $3,471,000 after acquiring an additional 4,231 shares during the last quarter. Finally, Bank of Nova Scotia increased its holdings in Abbott Laboratories by 53.7% during the 3rd quarter. Bank of Nova Scotia now owns 315,827 shares of the healthcare product maker’s stock valued at $42,302,000 after acquiring an additional 110,323 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the sale, the senior vice president directly owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. This trade represents a 1.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the sale, the vice president owned 24,628 shares of the company’s stock, valued at $2,846,504.24. This trade represents a 2.32% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ABT. Evercore reduced their price target on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Daiwa Securities Group dropped their price objective on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Leerink Partners reduced their target price on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research note on Friday, January 30th. Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Finally, Piper Sandler dropped their price target on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $136.16.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $107.99 on Friday. The company has a 50-day simple moving average of $114.58 and a 200-day simple moving average of $123.86. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The company has a market cap of $187.66 billion, a PE ratio of 29.03, a price-to-earnings-growth ratio of 1.72 and a beta of 0.74. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. The business had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.